Branched multi-functional macromonomers and related polymers and uses thereof
Disclosed are methods, compositions, reagents, systems, and kits to prepare and utilize branched multi-functional macromonomers, which contain a ring-opening metathesis polymerizable norbornene group, one or more reactive sites capable of undergoing click chemistry, and a terminal acyl group capable of undergoing a coupling reaction; branched multi-cargo macromonomers; and the corresponding polymers are disclosed herein. Various embodiments show that the macromonomers and polymers disclosed herein display unprecedented control of cargo loading of agents. These materials have the potential to be utilized for the treatment of diseases and conditions such as cancer and hypertension.
1. A macromonomer of Formula (II):
or a salt thereof, wherein:
each instance of R A is independently hydrogen, halogen, or substituted or unsubstituted, C 1-6 alkyl;
a is an integer from 1 to 20, inclusive;
each instance of M′ is independently a therapeutic agent, a diagnostic agent, or a prophylactic agent;
each instance of m′ is independently an integer from 2 to 10, inclusive;
each instance of L is independently substituted or unsubstituted, C 1-200 alkylene, substituted or unsubstituted, C 2-200 alkenylene, substituted or unsubstituted, C 2-200 alkynylene, substituted or unsubstituted, C 2-200 heteroalkylene, substituted or unsubstituted, C 2-200 heteroalkenylene, or substituted or unsubstituted, C 2-200 heteroalkynylene, wherein:
optionally one or more carbons in each instance of the substituted or unsubstituted, C 1-200 alkylene, substituted or unsubstituted, C 2-200 alkenylene, substituted or unsubstituted, C 2-200 alkynylene, substituted or unsubstituted, C 2-200 heteroalkylene, substituted or unsubstituted, C 2-200 heteroalkenylene, and substituted or unsubstituted, C 2-200 heteroalkynylene are independently replaced with substituted or unsubstituted carbocyclylene, substituted or unsubstituted heterocyclylene, substituted or unsubstituted arylene, or substituted or unsubstituted heteroarylene; and
optionally one or more heteroatoms in each instance of the substituted or unsubstituted, C 2-200 heteroalkylene, substituted or unsubstituted, C 2-200 heteroalkenylene, and substituted or unsubstituted, C 2-200 heteroalkynylene are independently replaced with substituted or unsubstituted carbocyclylene, substituted or unsubstituted heterocyclylene, substituted or unsubstituted arylene, or substituted or unsubstituted heteroarylene;
each instance of R B is independently hydrogen, halogen, or substituted or unsubstituted, C 1-6 alkyl;
each instance of b is independently an integer from 1 to 20, inclusive;
e is an integer from 1 to 10, inclusive;
X is OR c or N(R D ) 2 , wherein:
R c is hydrogen, substituted or unsubstituted, C 1-1000 alkyl, substituted or unsubstituted, C 2-1000 alkenyl, substituted or unsubstituted, C 2-1000 alkynyl, substituted or unsubstituted, C 1-1000 heteroalkyl, substituted or unsubstituted, C 2-1000 heteroalkenyl, substituted or unsubstituted, C 2-1000 heteroalkynyl, an oxygen protecting group, or a leaving group; and
each instance of R D is independently hydrogen, substituted or unsubstituted, C 1-1000 alkyl, substituted or unsubstituted, C 2-1000 alkenyl, substituted or unsubstituted, C 2-1000 alkynyl, substituted or unsubstituted, C 1-1000 heteroalkyl, substituted or unsubstituted, C 2-1000 heteroalkenyl, substituted or unsubstituted, C 2-1000 heteroalkynyl, or a nitrogen protecting group, or two R D are taken together to form a substituted or unsubstituted heterocyclyl or substituted or unsubstituted heteroaryl moiety; and
each instance of R 1 is independently hydrogen, halogen, substituted or unsubstituted, C 1-6 alkyl, or each instance of
2. A compound of Formula (III):
or a salt thereof, wherein:
L 1 is substituted or unsubstituted, C 1-20 alkylene or substituted or unsubstituted, C 2-20 heteroalkylene;
X 1 is O or NR I , wherein:
R I is hydrogen, substituted or unsubstituted, C 1-10 alkyl, substituted or unsubstituted, C 2-10 alkenyl, substituted or unsubstituted, C 1-10 heteroalkyl, substituted or unsubstituted, C 2-10 heteroalkenyl, or a nitrogen protecting group;
W, Y, and Z are each independently hydrogen, substituted or unsubstituted, C 1-100 alkylene, substituted or unsubstituted, C 2-100 heteroalkylene, or a group of formula (i), provided that at least one of W, Y, and Z is a group of formula (i),
wherein formula (i) is:
each instance of L is independently substituted or unsubstituted, C 1-200 alkylene, substituted or unsubstituted, C 2-200 alkenylene, substituted or unsubstituted, C 2-200 alkynylene, substituted or unsubstituted, C 2-200 heteroalkylene, substituted or unsubstituted, C 2-200 heteroalkenylene, or substituted or unsubstituted, C 2-200 heteroalkynylene, wherein:
optionally one or more carbons in each instance of the substituted or unsubstituted, C 1-200 alkylene, substituted or unsubstituted, C 2-200 alkenylene, substituted or unsubstituted, C 2-200 alkynylene, substituted or unsubstituted, C 2-200 heteroalkylene, substituted or unsubstituted, C 2-200 heteroalkenylene, and substituted or unsubstituted, C 2-200 heteroalkynylene are independently replaced with substituted or unsubstituted carbocyclylene, substituted or unsubstituted heterocyclylene, substituted or unsubstituted arylene, or substituted or unsubstituted heteroarylene; and
optionally one or more heteroatoms in each instance of the substituted or unsubstituted, C 2-200 heteroalkylene, substituted or unsubstituted, C 2-200 heteroalkenylene, and substituted or unsubstituted, C 2-200 heteroalkynylene are independently replaced with substituted or unsubstituted carbocyclylene, substituted or unsubstituted heterocyclylene, substituted or unsubstituted arylene, or substituted or unsubstituted heteroarylene; and
each instance of M′ is independently a therapeutic agent, a diagnostic agent, or a prophylactic agent.
3. A method of preparing a macromonomer of claim 1 , or a salt thereof, comprising coupling a compound of the formula:
or a salt thereof, with a compound of the formula: HOR c or HN(R D ) 2 , or a salt thereof.
4. A method of preparing a macromonomer of claim 1 , or a salt thereof, comprising coupling a compound of the formula:
or salt thereof, with a compound of Formula (III):
or a salt thereof, wherein:
L 1 is substituted or unsubstituted, C 1-20 alkylene or substituted or unsubstituted, C 2-20 heteroalkylene;
X 1 is O or NR I ;
R I is hydrogen, substituted or unsubstituted, C 1-10 alkyl, substituted or unsubstituted, C 2-10 alkenyl, substituted or unsubstituted, C 1-10 heteroalkyl, substituted or unsubstituted, C 2-10 heteroalkenyl, or a nitrogen protecting group;
W, Y, and Z are each independently hydrogen, substituted or unsubstituted, C 1-100 alkylene, substituted or unsubstituted, C 2-100 heteroalkylene, or a group of formula (i), provided that at least one of W, Y, and Z is a group of formula (i);
formula (i) is:
and
L and M′ are as defined in claim 2 ;
to provide the macromonomer, or salt thereof.
5. A polymer prepared by polymerizing a macromonomer of claim 1 , or a salt thereof, in the presence of a metathesis catalyst.
6. A method of preparing a polymer comprising polymerizing a macromonomer of claim 1 , or a salt thereof, in the presence of a metathesis catalyst.
7. A pharmaceutical composition comprising a polymer of claim 5 and optionally a pharmaceutically acceptable excipient.
8. A kit comprising:
a polymer of claim 5 ; and
instructions for using the polymer.
9. A method of delivering a therapeutic agent, a diagnostic agent, or a prophylactic agent to a subject comprising administering to the subject a polymer of claim 5 .
10. A method of delivering a therapeutic agent, a diagnostic agent, or a prophylactic agent to a cell comprising contacting the cell with a polymer of claim 5 .
11. A method of treating a disease or condition in a subject in need thereof comprising administering to or implanting in the subject in need thereof a therapeutically effective amount of a polymer of claim 5 ; wherein at least one instance of M′ is a therapeutic agent.
12. A method of diagnosing a disease or condition in a subject comprising administering to or implanting in the subject a diagnostically effective amount of a polymer of claim 5 ; wherein at least one instance of M′ is a diagnostic agent.
13. The macromonomer of claim 1 , or a salt thereof, wherein each instance of R A is hydrogen.
14. The macromonomer of claim 1 , or a salt thereof, wherein each instance of R 1 is hydrogen.
15. The macromonomer of claim 1 , or a salt thereof, wherein a is 3, 4, 5, or 6.
16. The macromonomer of claim 1 , or a salt thereof, wherein each instance of
17. The macromonomer of claim 1 , or a salt thereof, wherein at least one instance of L is substituted or unsubstituted, C 2-200 heteroalkylene, wherein one or more carbons and/or one or more heteroatoms of the substituted or unsubstituted, C 2-200 heteroalkylene are independently replaced with substituted or unsubstituted heteroarylene.
18. The macromonomer of claim 1 , or a salt thereof, wherein at least one instance of L is substituted or unsubstituted, C 2-200 heteroalkylene, wherein one or more carbons and/or one or more heteroatoms of the substituted or unsubstituted, C 2-200 heteroalkylene are independently replaced with
wherein the nitrogen atom labeled with “*” is closer to the attachment point labeled with “**” than the attachment point labeled with “***”.
19. The macromonomer of claim 1 , or a salt thereof, wherein at least one instance of M′ is a therapeutic agent.
20. The macromonomer of claim 1 , or a salt thereof, wherein at least one instance of M′ is an anti-cancer agent.
21. The macromonomer of claim 1 , or a salt thereof, wherein at least two instances of M′ are different from each other.
22. The macromonomer of claim 1 , or a salt thereof, wherein at least one instance of m′ is 2, 3, 4, or 5.
23. The macromonomer of claim 1 , or a salt thereof, wherein each instance of R B is hydrogen.
24. The macromonomer of claim 1 , or a salt thereof, wherein each instance of b is independently 1, 2, 3, or 4.
25. The macromonomer of claim 1 , or a salt thereof, wherein e is 2, 3, or 4.
26. The macromonomer of claim 1 , or a salt thereof, wherein X is N(R D ) 2 .
27. The macromonomer of claim 26 , or a salt thereof, wherein at least one instance of R D is substituted or unsubstituted, C 50-1000 heteroalkyl.
28. The polymer of claim 5 , wherein the weight average molecular weight of the polymer is between 3,000 and 1,000,000, inclusive, g/mol.
29. The method of claim 11 , wherein at least two instances of M′ are different from each other.
30. The method of claim 11 , wherein at least one instance of M′ is an anti-cancer agent, and the disease or condition is cancer.
31. The method of claim 11 , wherein the subject is a human.
32. The compound of claim 2 , or a salt thereof, wherein L 1 is substituted or unsubstituted, C 1-20 alkylene.
33. The compound of claim 2 , or a salt thereof, wherein L 1 is substituted or unsubstituted, C 2-20 heteroalkylene.
34. The compound of claim 2 , or salt thereof, wherein X 1 is NR I .
35. The compound of claim 2 , or salt thereof, wherein each instance of W, Y, and Z is independently a group of formula (i).
36. The compound of claim 2 , or salt thereof, wherein each instance of L is independently substituted or unsubstituted, C 1-200 alkylene or substituted or unsubstituted, C 2-200 heteroalkylene.